Anzeige
Mehr »
Sonntag, 05.07.2026 - Börsentäglich über 12.000 News
Milliardenkonkurrenten im Visier: Dieser KI-Wert gewinnt namhafte Großkunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41ESB | ISIN: CNE1000070H8 | Ticker-Symbol: 0DX
Frankfurt
03.07.26 | 15:25
5,600 Euro
+3,70 % +0,200
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
NANJING LEADS BIOLABS CO LTD Chart 1 Jahr
5-Tage-Chart
NANJING LEADS BIOLABS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
5,7506,00004.07.
5,8005,90003.07.

Aktuelle News zur NANJING LEADS BIOLABS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLEADS BIOLABS-B (09887): GRANT OF AWARDS PURSUANT TO THE H SHARE AWARD SCHEME1
25.06.LEADS BIOLABS CO., LTD.: Leads Biolabs Announces Partner Oblenio Bio's $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development5
25.06.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PARTNER OBLENIO CLOSES OVERSUBSCRIBED US$62 MILLION SERIES B FINANCING ROUND TO ACCELERATE CLINICAL DEVELOPMENT ...-
05.06.LEADS BIOLABS-B (09887): NEXT DAY DISCLOSURE RETURN-
05.06.LEADS BIOLABS-B (09887): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION-
NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln
28.05.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION OF PHASE II CLINICAL STUDY RESULTS OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ...1
20.05.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE ...-
19.05.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR ADVANCED EXTRAPULMONARY ...1
15.05.LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION1
15.05.LEADS BIOLABS-B (09887): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
15.05.LEADS BIOLABS-B (09887): POLL RESULTS OF THE ANNUAL GENERAL MEETING APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION2
14.05.LEADS BIOLABS-B (09887): INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY2
08.05.LEADS BIOLABS-B (09887): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION AND PROPOSED IMPLEMENTATION OF H SHARE ...-
06.05.LEADS BIOLABS CO., LTD.: LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis1
06.05.LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT - LBL-047 PRIORITIZED FOR CLINICAL DEVELOPMENT IN SJOGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND ...1
24.04.LEADS BIOLABS-B (09887): PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026-
24.04.LEADS BIOLABS-B (09887): (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION ...2
24.04.LEADS BIOLABS-B (09887): NOTICE OF ANNUAL GENERAL MEETING-
24.04.LEADS BIOLABS-B (09887): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT1
24.04.LEADS BIOLABS-B (09887): 2025 ANNUAL REPORT2
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1